A post-marketing study evaluating the lipid-altering efficacy and safety of approved dose ranges of rosuvastatin in Indian hyperlipidemia patients in routine clinical practice (ROSUVEES)

There is a dearth of studies comparing clinical outcomes of different approved starting doses (5, 10 and 20 mg) of rosuvastatin in Indian hyperlipidemic patients, in real life clinical settings. In this multi-centre, open-label, non-randomized, parallel group study, 219 Indian hyperlipidemic patients were allocated to therapy with either 5, 10 or 20 mg rosuvastatin, based on the judgement by their physicians as a part of routine clinical care....